Figure S8 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity

Figure S8 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity

<p>Figure S8R</p>

সংরক্ষণ করুন:

গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক:	Shiyi Yu (17079079) (author)
অন্যান্য লেখক:	Ying Wang (17079082) (author), Xue Gong (17079085) (author), Zhehao Fan (17079088) (author), Zheng Wang (17079091) (author), Zhengyan Liang (17079094) (author), Rui Wu (17079097) (author), Binjie Cao (17079100) (author), Ning Wang (17079103) (author), Caili Bi (17079106) (author), Dan Lv (17079109) (author), Haibo Sun (17079112) (author)
প্রকাশিত:	2025
বিষয়গুলি:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Breast Cancer Cell Cycle Signal transduction pathways Drug Resistance Regulation of gene expression in drug resistance Endocrine-Related Cancers
ট্যাগগুলো:	ট্যাগ যুক্ত করুন কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!

অনুরূপ উপাদানগুলি

Figure S1 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
অনুযায়ী: Shiyi Yu (17079079)
প্রকাশিত: (2025)

Figure S2 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
অনুযায়ী: Shiyi Yu (17079079)
প্রকাশিত: (2025)

Figure S3 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
অনুযায়ী: Shiyi Yu (17079079)
প্রকাশিত: (2025)

Figure S4 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
অনুযায়ী: Shiyi Yu (17079079)
প্রকাশিত: (2025)

Figure S5 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
অনুযায়ী: Shiyi Yu (17079079)
প্রকাশিত: (2025)

Figure S6 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
অনুযায়ী: Shiyi Yu (17079079)
প্রকাশিত: (2025)

Figure S7 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
অনুযায়ী: Shiyi Yu (17079079)
প্রকাশিত: (2025)

Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
অনুযায়ী: Seung Yeon Oh (15051017)
প্রকাশিত: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
অনুযায়ী: Yufang Bao (15386826)
প্রকাশিত: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
অনুযায়ী: Yufang Bao (15386826)
প্রকাশিত: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
অনুযায়ী: Yufang Bao (15386826)
প্রকাশিত: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
অনুযায়ী: Yufang Bao (15386826)
প্রকাশিত: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
অনুযায়ী: Yufang Bao (15386826)
প্রকাশিত: (2025)

Table ST8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
অনুযায়ী: Ossia M. Eichhoff (14964145)
প্রকাশিত: (2025)

Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
অনুযায়ী: Nicole A. Traphagen (16677391)
প্রকাশিত: (2025)

Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
অনুযায়ী: Nicole A. Traphagen (16677391)
প্রকাশিত: (2025)

Supplementary Data S8 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
অনুযায়ী: Naoual Menssouri (16617248)
প্রকাশিত: (2025)

Supplementary Table S8 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
অনুযায়ী: Laura E. Stevens (14961009)
প্রকাশিত: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
অনুযায়ী: Alex C.H. Liu (14961921)
প্রকাশিত: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
অনুযায়ী: Alex C.H. Liu (14961921)
প্রকাশিত: (2025)

Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
অনুযায়ী: Alex C.H. Liu (14961921)
প্রকাশিত: (2025)

Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
অনুযায়ী: Alex C.H. Liu (14961921)
প্রকাশিত: (2025)

Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
অনুযায়ী: Alex C.H. Liu (14961921)
প্রকাশিত: (2025)

Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
অনুযায়ী: Alex C.H. Liu (14961921)
প্রকাশিত: (2025)

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
অনুযায়ী: Seung Yeon Oh (15051017)
প্রকাশিত: (2025)

Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
অনুযায়ী: Seung Yeon Oh (15051017)
প্রকাশিত: (2025)

Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
অনুযায়ী: Seung Yeon Oh (15051017)
প্রকাশিত: (2025)

Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
অনুযায়ী: Seung Yeon Oh (15051017)
প্রকাশিত: (2025)

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
অনুযায়ী: Seung Yeon Oh (15051017)
প্রকাশিত: (2025)

Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
অনুযায়ী: Seung Yeon Oh (15051017)
প্রকাশিত: (2025)

Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
অনুযায়ী: Seung Yeon Oh (15051017)
প্রকাশিত: (2025)

Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
অনুযায়ী: Seung Yeon Oh (15051017)
প্রকাশিত: (2025)

Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
অনুযায়ী: Seung Yeon Oh (15051017)
প্রকাশিত: (2025)

Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
অনুযায়ী: Seung Yeon Oh (15051017)
প্রকাশিত: (2025)

Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
অনুযায়ী: Seung Yeon Oh (15051017)
প্রকাশিত: (2025)

Figure 1 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
অনুযায়ী: Marta J. Llorca-Cardenosa (14961612)
প্রকাশিত: (2025)

Figure 2 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
অনুযায়ী: Marta J. Llorca-Cardenosa (14961612)
প্রকাশিত: (2025)

Figure 3 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
অনুযায়ী: Marta J. Llorca-Cardenosa (14961612)
প্রকাশিত: (2025)

Figure 4 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
অনুযায়ী: Marta J. Llorca-Cardenosa (14961612)
প্রকাশিত: (2025)

Figure 5 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
অনুযায়ী: Marta J. Llorca-Cardenosa (14961612)
প্রকাশিত: (2025)

Cannot write session to /tmp/vufind_sessions/sess_pp4vud8t1rqib9a7a3tmq3t21l